Kluwer Patent Blog

Fettsäuren, Federal Court of Justice (Bundesgerichtshof), 24 September 2013

Thorsten Bausch (Hoffmann Eitle) · Wednesday, February 12th, 2014

The later finding of the biological relationships underlying the activity of a drug does not constitute a new teaching for technical action if the indication, the dosage and the way of using the drug coincide with an the prior disclosed use of a drug for the treatment of a disease (confirmed by FCJ 9 June 2011 – X ZR 68/08, GRUR 2011, 999 – "Memantine"). The selection of a value within a known range does not render an invention patentable, unless for special circumstances (e.g. the dosage instruction achieves a particular technical effect vis à vis the prior art).

A full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer

Leading change



This entry was posted on Wednesday, February 12th, 2014 at 12:00 pm and is filed under Case Law, Germany, Inventive step, Novelty

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.